Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
 

Learn about the flu shot, COVID-19 vaccine, and our masking policy »

Stanford Health Care

Anaplastic Thyroid Carcinoma, Version 2.2015 JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK Haddad, R. I., Lydiatt, W. M., Ball, D. W., Busaidy, N. L., Byrd, D., Callender, G., Dickson, P., Duh, Q., Ehya, H., Haymart, M., Hoh, C., Hunt, J. P., Iagaru, A., Kandeel, F., Kopp, P., Lamonica, D. M., McCaffrey, J. C., Moley, J. F., Parks, L., Raeburn, C. D., Ridge, J. A., Ringel, M. D., Scheri, R. P., Shah, J. P., Smallridge, R. C., Sturgeon, C., Wang, T. N., Wirth, L. J., Hoffmann, K. G., Hughes, M. 2015; 13 (9): 1140-1150

Abstract

This selection from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Thyroid Carcinoma focuses on anaplastic carcinoma because substantial changes were made to the systemic therapy recommendations for the 2015 update. Dosages and frequency of administration are now provided, docetaxel/doxorubicin regimens were added, and single-agent cisplatin was deleted because it is not recommended for patients with advanced or metastatic anaplastic thyroid cancer.

View details for Web of Science ID 000361419800013

View details for PubMedID 26358798

View details for PubMedCentralID PMC4986600